Skip to main content
. Author manuscript; available in PMC: 2019 Apr 2.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2017 Oct 28;100(2):490–497. doi: 10.1016/j.ijrobp.2017.10.030

Fig. 2.

Fig. 2.

Predictors of distant failure in patients with resectable pancreatic cancer. Tumors from patients with resectable pancreatic cancer were obtained at the time of surgery. Immunohistochemistry (IHC) was performed for the proteins thymidylate synthase (TS) and DPC4 (SMAD4). A pathologist scored each stained section from 0 (no staining) to 3 (strong staining) from paired samples from each tumor. For TS a score greater than 1 was considered high risk, and for DPC4 the absence of staining in a core was considered high risk. Patients who did not experience a distant failure were censored at last follow-up or death. The loss of DPC4 (A) or high TS expression (B) was associated with a shorter time to distant failure in patients with resectable pancreatic cancer.